As of the most recent data (March 2026), SXTC shows a profit margin of -290.71%. That compares with 70.0% in the prior-year period — down 515.3% year over year. That is below the Consumer Discretionary sector average of 10.25%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SXTC's profit margin is now -290.71% (was 70.0%) — a 515.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether China SXT Pharmaceuticals is outperforming or lagging.

The Consumer Discretionary sector average profit margin is about 10.25%. China SXT Pharmaceuticals is at -290.71%, which is lower that average. That is roughly 2935.6% below the sector mean. Use the comparison chart on this page to see how SXTC stacks up against individual peers as well.

That compares with 70.0% in the prior-year period — down 515.3% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare China SXT Pharmaceuticals with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has China SXT Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -290.71%) with ownership activity and broader fundamentals.